BSE · 541299
Dr Lalchandani Labs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹4 Cr with net profit ₹0 Cr — a 9.35% net margin, versus 12.24% the period before.
Shareholding
As of 2026-03-31
- Promoter32.9%
- Public67.1%
233 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 4.44× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Healthcare · ranked #1 of 79 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.06 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.33 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹31,931 Cr | 752.83 | 14.2 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.48 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
| Dr Lalchandani Labs Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashDr Lalchandani Labs Limited is listed on the Indian markets with a market capitalization of Rs 12 Cr. The company's 52-week high is Rs 28.7 and its low is Rs 6.46. As of March 31, 2026, promoter holding stands at 32.9025%, with public holding at 67.0975%.
Positives
- +The debt-to-equity ratio is 0.39.
- +The book value per share is Rs 22.33.
- +Promoter pledge is 0% as of March 31, 2026.
Negatives
- −Revenue decreased by 11.41% from Rs 5.0451 Cr in March 2024 to Rs 4.4612 Cr in March 2025.
- −Net profit decreased by 32.59% from Rs 0.6175 Cr in March 2024 to Rs 0.4172 Cr in March 2025.
- −Promoter holding decreased from 60.784% in March 2022 to 32.9025% in March 2026.
- −The company is under LT-ASM surveillance, specifically ASM 1.
- −No quarterly results have been disclosed.
Financial performance
The company's revenue decreased to Rs 4.4612 Cr in March 2025 from Rs 5.0451 Cr in March 2024. Net profit for March 2025 was Rs 0.4172 Cr, a decrease from Rs 0.6175 Cr in March 2024. Earnings per share (EPS) also decreased from Rs 1.43 in March 2024 to Rs 0.96 in March 2025.
Profitability & returns
The company recorded a net profit of Rs 0.4172 Cr in March 2025, which is a decline from Rs 0.6175 Cr in March 2024. EBITDA for March 2025 was Rs 0.3663 Cr, increasing from -Rs 0.1891 Cr in March 2024. EPS for March 2025 was Rs 0.96.
Balance sheet
The company has a debt-to-equity ratio of 0.39. Book value per share is Rs 22.33. There is no information available for dividends.
Ownership & pledges
As of March 31, 2026, promoter shareholding was 32.9025%, with public shareholding at 67.0975%. The number of shareholders as of March 31, 2026, was 233. There are no pledged promoter shares.
Regulatory & surveillance
The company is currently under LT-ASM surveillance, specifically ASM 1.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Dr Lalchandani Labs Limitedshare price & fundamentals